Luncheon Symposium 7【Bayer】
15 Aug 2025
12:00
13:00
TICC - 2F 201BC
Integrating Radioligand Therapy into mCRPC Clinical Practice: From Taiwan and Japan Experience
Introduce the treatment options and trends for mCRPC (metastatic castration-resistant prostate cancer) medications and share the Xofigo real-world data from Taiwan and Japan.
| Time | Session |
|---|---|
|
12:00
13:00
|
|